1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Semaglutide
Trade Name:
Ozempic
Manufacturer/Distributor:
Novo Nordisk
www.novonordisk.ca
Classification:
Incretin mimetic
ATC Class:
A10BJ06 - semglutide
Status:
active
Notice of Compliance (yyyy/mm/dd):
2018/01/04
Date Marketed in Canada (yyyy/mm/dd):
2018/02/22
Presentation:
Injection: 1.34 mg/mL. DIN: 02471469
Injection: 1.34 mg/pen. DIN: 02471477
Comments:
Semaglutide is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise, metformin, metformin and a sulfonylurea, or basal insulin with metformin.
Back to:
Drug Product Listings 
